Frontiers in NeuroanatomyNeurosciencePeer-reviewed journal article
Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy
Alberto J. RicoiD, Almudena CorchoiD, Julia ChocarroiD, Goiaz AriznabarretaiD, Elvira RodaiD, Adriana HonrubiaiD, Patricia ArnaiziD, José Luis LanciegoiD
Abstract
The presence of a widespread cortical synucleinopathy is the main neuropathological hallmark underlying clinical entities such as Parkinsons disease with dementia (PDD) and dementia with Lewy bodies (DLB). There currently is a pressing need for the development of non-human primate (NHPs) models of PDD and DLB to further overcome existing limitations in drug discovery. Here we took advantage of a retrogradely-spreading adeno-associated viral vector serotype 9 coding for the alpha-synuclein A53T mutated gene to induce a widespread synucleinopathy of cortical and subcortical territories innervating the putamen. Four weeks post-AAV deliveries animals were sacrificed and a comprehensive biodistribution study was conducted, comprising the quantification of neurons expressing alpha-synuclein, rostrocaudal distribution and their specific location. In brief, cortical afferent systems were found to be the main contributors to putaminal afferents (superior frontal and precentral gyrus in particular), together with neurons located in the caudal intralaminar nuclei and in the substantia nigra pars compacta (leading to thalamostriatal and nigrostriatal projections, respectively). Obtained data extends current models of synucleinopathies in NHPs, providing a reproducible platform enabling the adequate implementation of end-stage preclinical screening of new drugs targeting alpha-synuclein.
- Citations
- 10
- FWCI
- 2.66
- Field percentile
- top 10%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Versatile AAV-TH-SNCA Model to Study Early α-Synuclein Pathology and Intervention
Sabina Marciano, Leandra G. Velazquez, … Roberta Marongiu·bioRxiv·Apr 30, 2026
- A viral vector model for circuit-specific synucleinopathy
Alexia Lantheaume, Nina Schöneberg, … Philip Tovote·bioRxiv·Aug 28, 2023
- Overexpression of alpha synuclein in Midbrain Dopamine Neurons Reduces Dopamine Release Without Cell Loss and Drives Mild Motor Deficits in Mice
Kelsey Barcomb, Jen-Hsiang T. Hsiao, … Alexandra Nelson·bioRxiv·Mar 17, 2025
- Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration
Sofia Ines Garcia Moreno, Fabian Limani, … Thomas Steinkellner·Experimental NeurologyPeer-reviewed·Sep 15, 2024
- In vivo validation of novel non-invasive PHP.eB AAVs as a potential therapeutic approach for alpha-Synucleinopathies
Maria Fouka, Iraklis Tsakogias, … Maria Xilouri·Acta Neuropathologica CommunicationsPeer-reviewed·Sep 29, 2025
- Intranigral injection of Alpha-Synuclein pre-formed fibrils leads to BBB compromise and Bilateral Dopaminergic Neurodegeneration in A53T Alpha-Synuclein transgenic mice.
Soumitra Ghosh, Han Lin, … William J. Meilandt·Discover NeurosciencePeer-reviewed·Aug 27, 2026